Objectives: Very few studies have examined the quality of wedge resection in patients with non-small cell lung cancer. Using the National Cancer Database, we evaluated whether the quality of wedge resection affects overall survival in patients with early disease and how these outcomes compare with those of patients who receive stereotactic radiation.
Wedge resection quality and survival versus stereotactic radiation.
Central Message
Number of nodes examined and margin status are important quality metrics of a wedge resection. High-quality wedge appears superior to lower-quality wedge and to stereotactic radiation.
Perspective
Our data show that only 3.0% of wedge patients are nodally upstaged, far less than for lobectomy. The quality of resection (on the basis of nodes assessed and margin status) appears to affect survival, including compared with stereotactic radiation. When offering patients a therapeutic wedge resection, every effort should be made to achieve negative margins and perform a regional lymph node assessment.
See Editorial Commentary page 392.
See Editorial page 376.
For patients with early-stage non-small cell lung cancer (NSCLC) not fit for lobectomy, treatment options include surgery with sublobar resection (segmentectomy or wedge) or radiotherapy, now most commonly with hypofractionated stereotactic body radiation therapy (SBRT). There remains significant uncertainty about which treatment modality confers superior survival. A retrospective database study has shown a survival benefit for wedge resection over SBRT in this setting. 1 However, clinical trials attempting to compare SBRT with lobectomy in surgically amenable patients have closed early because of insufficient enrollment, [2] [3] [4] and trials of SBRT to sublobar resection are ongoing. 5, 6 One specific concern with SBRT is the lack of pathologic nodal assessment. In patients with clinical stage I disease who undergo lobectomy, the nodal upstaging rate is as high as 19%. 7 Because pathologic stage II patients are typically referred for adjuvant chemotherapy, 8 a wedge resection with adequate margins and lymph node (LN) sampling could identify those patients and provide prognostic as well as treatment benefit.
The data on the quality of nonanatomic resection are, however, limited. Planned subgroup analysis of the American College of Surgeons Oncology Group (ACOSOG) Z4032 trial showed small margins (48%<1 cm) and limited nodal assessment (41% of patients had no nodes assessed) in patients who underwent wedge resection, with <1% of patients upstaged nodally. 9 This was a small sample with only 153 patients, thus a better appreciation of the quality of wedge resection in a much larger, more generalizable cohort of patients would have significant implications in the therapies offered for patients not fit for anatomic resection. Further, a comparison of the quality of a wedge resection with SBRT would provide valuable information to patients and clinicians planning the initial treatment course when lobectomy is not feasible.
We aimed to assess the surgical quality, on the basis of margin status and nodal sampling, in patients who undergo wedge resection for early-stage NSCLC and its effect on pathologic upstaging and overall survival. We aimed to quantify the number of nodes sampled, the rate of pathologic upstaging compared with patients who underwent lobectomy, and any survival difference on the basis of nodal assessment and margin status, among patients who underwent wedge resection and, as a secondary aim, relative to patients who received primary SBRT.
METHODS

Data Source
The National Cancer Database (NCDB) is a joint project of the American Cancer Society and the Commission on Cancer (CoC) of the American College of Surgeons. It captures approximately 70% of all newly diagnosed cancers in the United States (including approximately 80% of lung cancers), 10 from approximately 1500 CoC-accredited facilities nationwide, with which the American College of Surgeons has established data usage agreements. Because the NCDB does not contain personal health information, our institutional review board approval does not consider it human subject research and thus approved the study without the need for formal review.
Study Population
Using the NCDB NSCLC participant user file, we identified patients with early-stage NSCLC treated with either a wedge resection or SBRT. We excluded those with a tumor of a main bronchus or unknown lung lobe as well as those with any additional cancer(s). Patients were limited to those with a major invasive non-small-cell histologic subtype: large cell, squamous cell, adenocarcinoma, or bronchoalveolar carcinoma. Patients with primary lung neuroendocrine tumors (carcinoid), were also excluded because of their more indolent behavior and very different biology.
Using the American Joint Committee on Cancer seventh edition criteria, 11 we limited our cohort to patients with clinical T1 to T2, N0, M0 tumors <4 cm in size, because SBRT is unlikely to be an option for larger tumors. We then excluded patients not treated with a wedge resection or SBRT, including those who received neoadjuvant therapy. Details on determination of SBRT in the NCDB have been previously published. 12 Because we planned to propensity score-match wedge and SBRT patients, those with a documented contraindication to surgery or radiation or an unknown reason for not receiving surgery or radiation were excluded (n ¼ 1981), because these patients would be unable to receive the other treatment. Finally, those with missing data and those diagnosed before 2005 were excluded (n ¼ 24,916; Figure 1 ).
Surgical Quality Variables
For patients who underwent wedge resection, we considered 2 variables as potentially important quality indicators: the number of LNs examined and surgical margins. As an aggregate quality marker, we grouped these 2 variables together into: positive margins (R1/R2), negative margins with 5 LNs examined, and negative margins with >5 LNs examined. Several studies have shown that increased LN assessment (up to 21 nodes) is associated with improved overall survival in patients who undergo lobectomy. Because patients who undergo wedge resection have much smaller specimens with fewer N1 nodes, we chose a cutoff of 5 nodes because it is more reflective of systematic sampling of mediastinal nodes. [13] [14] [15] This cutoff was extrapolated from LN counts from the ACOSOG Z0030 trial, and the CoC guidelines of 10 nodes assessed, which is primarily for patients who undergo anatomic resection.
Statistical Analysis
Analyses were first conducted only among patients who received a wedge resection.
We first examined the distribution of the number of LNs examined and how often patients were pathologically upstaged to pN1 to N3, on the basis of the number of nodes examined. The number of nodes examined and margins obtained were then used to assess the surgical quality of resection. We then examined differences in overall survival from diagnosis according to surgical quality, using Kaplan-Meier curves and Cox proportional hazards regression. Patients who were alive at 96 months of follow-up were censored at this date because of the very small number of patients who survived beyond this time (n ¼ 335). Cox regression results were adjusted for age, gender, race, insurance, socioeconomic status (on the basis of an aggregate of county-level income and education available in the NCDB), comorbidity (using the Deyo modification of the Charlson index 16 ), lung lobe of the primary tumor, histologic subtype, clinical T classification, year of diagnosis, and treatment facility type.
Next, we used multivariable conditional logistic regression to analyze factors associated with receiving a high quality (negative margins with >5 LNs examined) or low quality (R1/R2) surgery (vs average quality [negative margins with 0-5 LNs examined]), adjusting for the same demographic and clinical factors as stated previously. We evaluated factors associated with having 0 LNs examined using multivariable ordinary logistic regression.
Propensity Score-Matched Cohort
Finally, to compare survival differences between wedge resections of varying quality to SBRT, we developed a subcohort of propensity score-matched wedge and SBRT patients. A propensity score was computed for each patient using a logistic regression model containing relevant demographic and clinical factors, determined a priori on the basis of relevance for survival analysis: age, sex, race, socioeconomic status, comorbidity score, lung lobe of primary tumor, histologic subtype, clinical T stage, year of diagnosis, and treatment facility type. Wedge and SBRT patients were then matched 1:1 without replacement using the nearest neighbor method with a caliper width ¼ 0.2 3 SD of logit of propensity score ¼ 0.225. Differences in demographic and clinical characteristics of matched wedge and SBRT patients were assessed using standardized mean differences. Standardized difference plots and mirror histograms were also used to show subcohort balance after matching ( Figure E1 ). Reporting of propensity-matching methods and results was done in accordance with journal guidelines. 17 Overall survival from diagnosis was analyzed in this cohort using Kaplan-Meier curves and Cox regression adjusting for demographic and clinical factors as mentioned previously, to account for residual confounding between wedge resection quality subgroups. Analyses were performed using Stata Version 14.2 (StataCorp, College Station, Tex). 18 All tests were 2-sided and P<.05 was considered statistically significant.
RESULTS
Wedge Resection Quality Assessment
We identified 14,328 patients diagnosed with an earlystage NSCLC from 2005 to 2013 treated with a wedge resection (n ¼ 10,032) or SBRT (n ¼ 4296; Figure 1 ). Among those who received a wedge resection, 44.3% had 0 LNs examined, 38.5% had only 1 to 5 examined, and the remaining 17.1% had>5 examined. The overall upstaging rate was 3.0% (5.2% among those who had at least 1 LN examined) and increased with increasing numbers of nodes examined: 1 to 5 LNs (4.4%); 6 to 10 LNs (6.3%); and >10 LNs (8.1%). Patients were most often upstaged to N1 (1.2%) or N2 (1.7%). Increasing nodal assessment was primarily associated with increased N1 upstaging, rather than N2. Although the rate of N2 upstaging was relatively constant the N1 upstaging rate increased from 1.6% for patients with 1 to 5 nodes examined, to 4.2% for patients with >10 nodes examined. Most patients (94.6%), had a negative-margin resection. Overall, 16.7% of patients had the highest-quality resection, with negative margins and >5 nodes examined. Characteristics of wedge resection patients are presented in Table 1 , overall as well as stratified according to surgical quality.
The surgical quality of the wedge resection was significantly associated with overall survival (Figure 2 Those with negative margins also had a significantly lower risk of death (Figure 2 , B; log-rank P <.001; aHR, 0.58; FIGURE 1. Cohort selection from the National Cancer Database nonsmall cell lung cancer (NSCLC) participant user file. NSC, Non-small cell; CT, chemotherapy; RT, radiation therapy; SBRT, stereotactic body radiation therapy. The Journal of Thoracic and Cardiovascular Surgery c Volume 156, Number 1 383 95% CI, 0.52-0.66, for negative margins vs positive margins). Aggregating the number of LNs examined and margin status together showed that the 3 quality groups experienced significantly distinct survival (Figure 2 , C; log-rank P<.001). For low-quality resection (R1/R2), median survival was 40.1 months (IQR, 33.7-45.8). For average-quality resection (negative margins with 5 LNs examined), median survival was 65 months (IQR, 62.9-66.9) and these patients were 40% less likely to die compared with the low-quality group (aHR, 0.61; 95% CI, 0.54-0.68). At 96 months of follow-up, median survival
was not yet achieved for high-quality resection patients. This high-quality group was less than half as likely to die (aHR, 0.45; 95% CI, 0.39-0.52) compared with the lowquality group, and 25% less likely to die compared with the medium-quality group (aHR, 0.75; 95% CI, 0.68-0.82).
Having established the importance of a higher-quality surgery, we next sought to determine which factors were associated with receiving the lowest-and highest-quality resections (Table 2) . Compared with those with an averagequality resection, patients with a high-quality resection were more likely to be younger (odds ratio [OR], 0.84; 95% CI, 0.79-0.90, per 10-year increase in age), have less comorbidity (OR, 0.68; 95% CI, 0.59-0.80, for Charlson score 2 vs 0), and were more likely to be treated at an academic center (OR, 1.40; 95% CI, 1.25-1.56 for academic vs community cancer center). The likelihood of receiving a high-quality surgery also increased over time (OR, 1.04; 95% CI, 1.02-1.06, per 1-year increase). In contrast, patients receiving a low-quality resection (vs those with an average-quality resection) tended to be older (OR, 1.14; 95% CI, 1.02-1.28, per 10-year increase) and had larger tumors (OR, 2.65; 95% CI, 2.16-3.24, for cT2 vs cT1).
As a supplementary analysis, we also evaluated risk factors for having 0 LNs examined. Patients having 0 LNs examined tended to be older (OR, 1.15; 95% CI, 1.09-1.21, per 10-year increase), have more comorbidity (OR, 1.13; 95% CI, 1.01-1.26, for Charlson score 2 vs 0), and treated at a nonacademic center (OR, 0.76; 95% CI, 0.70-0.83, for academic vs nonacademic; Table E1 ).
Wedge Resection and SBRT
Among the entire cohort, patients who received SBRT were, on average, 5 years older (74.7 vs 69.9 years) and were less likely to have private insurance (11.6% vs 22.8%) compared with those who received a wedge resection (Table 3) . They also, however, tended to have less comorbidity (56.0% vs 41.0% Charlson score of 0) and smaller tumors (81.5% vs 86.9% T1) than those who received a wedge. SBRT use also increased over time (P <.001). Among SBRT patients, 111 had at least 1 LN assessed (2.6%). There was no difference in survival compared with SBRT patients without nodes assessed (data not shown). Utilization of adjuvant chemotherapy was higher among wedge patients (5.0% for N0 patients; 64.7% for N1-N3 patients) than SBRT patients (0.7%). For the subsequent propensity match, 3867 of 4296 SBRT patients (90%) were matched with an equal number of wedge patients. Within this matched cohort, there were no significant differences between wedge and SBRT patients on any characteristics examined (standardized mean difference<0.1 for all characteristics; Table 3 ), indicating good covariate balance between treatment groups. A standardized difference plot and mirror histogram showing subcohort balance after propensity scorematching are presented in Figure E1 .
Finally, we compared overall survival of patients who received SBRT with patients who received wedge resection. Within the entire cohort, wedge patients had significantly better survival compared with SBRT patients (log-rank P <.001; Figure 3, A) , and remained at a lower hazard of death in multivariable analysis (aHR, 0.66; 95% CI, 0.61-0.70).
Aggregating the 2 quality metrics of nodal assessment and margin status together, SBRT showed worse overall survival (Figure 3, B) and increased hazard of death compared with a margin-negative resection regardless of the number of nodes examined (>5 nodes: aHR, 0.50; 95% CI, 0.43-0.58; 5 nodes: aHR, 0.65; 95% CI, 0.60-0.70). There was no significant difference in the risk of death however, between a margin-positive resection and SBRT (aHR, 1.13; 95% CI, 0.95-1.36).
DISCUSSION
We show here that the number of LNs examined and margins obtained are important-quality markers in wedge resection for early-stage NSCLC. Further, despite overall low upstaging rates, a margin-negative wedge resection showed improved overall survival compared with SBRT, regardless of the number of nodes assessed, whereas SBRT did not show a difference compared with a marginpositive resection.
One of the purported benefits of a resection is the ability to pathologically evaluate LNs. Unfortunately, patients who undergo wedge resection have very low rates of LN node assessment. In a subgroup analysis of patients who undergo nonanatomic resection within the ACOSOG Z4032 trial, 41% did not undergo any LN assessment. A more recent analysis of nodal assessment in sublobar resection by David et al showed similar findings. 19 Within our cohort, 44% of patients had no LNs assessed. As expected, improved node retrieval was associated with increased upstaging, although at a rate significantly lower than what is reported in the literature during anatomic resection (3% for wedge in our population vs up to 20% for anatomic resection in the literature). 7 However, this was higher than the 1% seen in the subgroup analysis of the ACOSOG Z4032 trial. The number of nodes examined did correlate with likelihood of upstaging as well as with overall survival, suggesting the importance of nodal assessment despite the overall low upstage rate. Others have also reported this association in similar studies of early-stage NSCLC, but not separately for wedge resection. 14, [19] [20] [21] [22] [23] There remains no clear consensus on the optimal treatment for patients not fit to undergo lobectomy. Multiple randomized trials of SBRT versus anatomic resection closed early because of failure to enroll sufficient patients.
3,4 Trials specifically evaluating SBRT and sublobar resection in patients unfit for anatomic resection are under way. 5, 6 Outcome measures between wedge resection and SBRT have been evaluated in a number of observational studies. [24] [25] [26] [27] [28] [29] Many of these studies have shown superior overall survival among surgical patients but were underpowered and lacked statistical significance. A notable exception is the recent analysis of the NCDB by Yerokun et al, who reported wedge resection to be significantly superior to SBRT for 5-year overall survival (31.0% for SBRT vs 49.9% for wedge resection; P < .001).
1 This improvement in overall survival also might also drive an observed cost-effectiveness benefit to surgery over SBRT, despite its higher cost. 30 In contrast, differences in diseasespecific survival appear to be smaller and generally nonsignificant. 25, 26 Thus, differences between study results might be driven by end point selection, especially because of residual confounding in observational studies. Of note, ongoing trials of SBRT versus sublobar resection plan to evaluate overall survival as the primary outcome measure.
Importantly, none of these studies considered the surgical quality of the wedge resection performed. Within patients with early stage NSCLC who undergo anatomic resection, meeting specific quality markers has been associated with improved outcomes. 31 We show that this also applies to patients who undergo nonanatomic resection, with high-quality wedge resection showing improved outcomes in relation to a lower-quality resection as well as to SBRT. Clinicians caring for these patients should therefore consider the quality of surgery feasible in advising patients about surgery over nonoperative management and in considering the extent of nodal surgery to perform. However, prospective, randomized data are needed to clearly define the optimal treatment modality in these patients.
There are several important limitations to our work. Because this was a retrospective review, we cannot show causal inferences. No data on pulmonary function tests are available in the NCDB, thus we could not assess differences in pulmonary disease between wedge and SBRT patients. Although SBRT patients in general might be sicker than wedge patients, we excluded those with a documented contraindication to surgery. Further, SBRT patients in our cohort had a lower comorbidity score, which includes presence of chronic pulmonary disease, 16 and our findings were unchanged in sensitivity analysis of patients with a comorbidity score of 0. Our estimate of the number of LNs examined might be affected by differing institutional or practitioner policies on how to count fragments of nodes. Further, we were unable to assess nodal stations because these data are unavailable in the NCDB. There is also no way to clearly know in the NCDB if tumors are located centrally or peripherally, which can affect the nodal stations easily accessible during nonanatomic resection. Additionally, patients with central tumors are less likely to be able to undergo wedge resection, and this selection bias might affect the outcomes. With respect to margin status, the NCDB only codifies as positive or negative. Other studies have shown that the size of the margin also plays a role, and we were not able to assess that. Finally, we were unable to examine disease-specific survival, recurrence, or other outcome measures in this study.
CONCLUSIONS
LN evaluation and margin status are important surgical quality markers that are associated with overall survival in wedge resection for early-stage NSCLC. Margin-negative resection appears superior to SBRT regardless of the number of nodes assessed, however a margin-positive resection appears nonsuperior to SBRT. Prospective, randomized trials are needed to clarify the optimal treatment modality in patients not fit for lobectomy. Clinicians should consider the quality of surgery feasible in treatment recommendations for these patients (Video 1). Congratulations, Dr Krantz and team. I enjoyed reading the paper. Essentially, wedge resections, for a variety of reasons, continue to be performed in a meaningful minority of patients in the country, as you have just shown, and this is largely due to the 3 failed trials that they have been unable to accrue, 2 in patients who have marginal lung function and they are evaluating for a sublobar resection versus nonoperative therapy, namely, stereotactic body radiation therapy.
Webcast
From your data set I see 2 main findings, and a very brief comment about both of them, the first one being that in less than 20% of patients, or about 18% of patients who undergo wedge resection, who have negative margins and a suboptimal number of lymph nodes, there are several factors that lead to these patients having a suboptimal number of lymph nodes. It is hard to evaluate these factors from a large database study. Essentially, as several groups, including ours, have shown, the degree of involvement of the surgeon and the pathologist, how the staple line is evaluated, and whether the surgeon and the pathologist look at the specimen together affects the number of lymph nodes in any specimen, be it a wedge resection or a lobectomy specimen. Similarly, your other main finding, being that wedge resection with negative margins with an adequate number of lymph nodes or without an adequate number of lymph nodes tends to have better overall survival than stereotactic radiation therapy, matching, unfortunately, any large data set, only accounts for variables that are present within the data set, and that continues to be a problem no matter which data set you use, the National Cancer Database, SEER-Medicare, or matched studies of the STS data that we are seeing at this point in time.
So in summary, I interpret your findings that a wedge resection is not inferior to stereotactic radiation and might be superior if you have a good number of lymph nodes that you excise, and second, probably more importantly, 
